10-Q/A: SS Innovations International Restates Financials After Identifying Material Errors

SS Innovations International restated its previously issued interim financial statements for the quarter ended September 30, 2023, due to material errors discovered during an internal review and re-audit.

Summary

• SS Innovations International, Inc. restated its interim unaudited condensed consolidated financial statements for the quarter ended September 30, 2023.
• The restatement was due to material errors discovered in prior filings, including the 2023 Form 10-K and Subject Forms 10-Q.
• The errors stemmed from accounting for the merger transaction, functional reclassifications, revenue recognition for deferred payment sales, recognition of right of use assets and liabilities, and other adjustments.
• Management concluded that the company's disclosure controls and procedures and internal controls over financial reporting were not effective as of September 30, 2023, due to material weaknesses related to the accounting errors.
• The company is taking remedial actions to address these weaknesses.
• The restatement impacts several items in the Form 10-Q, including financial statements, management's discussion and analysis, controls and procedures, and legal proceedings.
• As of January 14, 2025, there were 170,873,415 shares of common stock outstanding.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the restatement of financials, material weaknesses in internal controls, and net losses. However, there are some positive aspects such as increased revenue and improved working capital.

Positives

• Revenue increased significantly for both the three and nine months ended September 30, 2023, compared to the same periods in 2022.
• The company converted $16,980,000 in debt to equity, improving its stockholders equity and working capital position.
• The company has a working capital surplus of $14,215,627 as of September 30, 2023.
• Gross profit increased to $298,848 for the three months ended September 30, 2023, compared to $240,578 for the same period in 2022.
• Gross profit increased to $1,144,492 for the nine months ended September 30, 2023, compared to $240,578 for the same period in 2022.

Negatives

• The company restated its financial statements due to material errors, indicating weaknesses in internal controls.
• The company reported a net loss of $1,898,538 for the three months ended September 30, 2023.
• The company reported a net loss of $8,736,042 for the nine months ended September 30, 2023.
• The company identified material weaknesses in its disclosure controls and procedures and internal control over financial reporting.
• Selling, general and administrative expenses increased significantly for both the three and nine months ended September 30, 2023, compared to the same periods in 2022.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional resources.
• The company's existing cash resources and income from operations are not expected to provide sufficient funds to carry out operations and business development through the next twelve months.
• There is no assurance that the company will be able to raise additional equity capital or be successful in generating additional revenues and ultimately achieving profitability.
• The company faces risks related to protecting its intellectual property rights and avoiding violation of the intellectual property rights of others.
• The company's financial performance is dependent on obtaining regulatory approvals in various regulated markets.
• The company is involved in litigation in the Bahamas regarding ownership of shares in Otto Pvt Ltd.

Future Outlook

The company plans to raise additional capital through further private or public offerings to scale up operations, incur capital expenditure, and finance research and development.

Management Comments

• Management recognizes that the Company must obtain additional resources to successfully implement its business plans.
• While management of the Company believes that it will be successful in its capital formation and planned expansion of its operating activities, there can be no assurance that the Company will be able to raise additional equity capital or be successful in generating additional revenues and ultimately achieving profitability.

Industry Context

The company operates in the surgical robotics industry, which is experiencing increasing recognition of robotically assisted surgeries as an approved treatment modality from an insurance coverage perspective.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• A thorough comparison would require benchmarking against competitors like Intuitive Surgical, Stryker, and Medtronic in terms of revenue growth, R&D spending, and profitability metrics.
• Additionally, comparing the company's gross margins and operating expenses to industry averages would provide valuable insights.

Legal Proceedings

• An ex-shareholder of Otto Pvt Ltd. commenced litigation in the Bahamas, seeking legal confirmation that it holds 9,000 shares in Otto.
• The Bahamian court has issued an interim order to maintain the status quo with respect to the 9,000 Otto shares and SSI-Indias assets during the pendency of the litigation.
• Dr. Srivastava and the Company have entered into an Indemnification Agreement on October 12, 2024, pursuant to which Dr. Srivastava has agreed to fully indemnify the Company for any claims, damages and costs (including legal fees) which it incurs in connection with this litigation.

Related Party Transactions

• On April 15, 2023, the Company executed a Convertible Promissory Note with Sushruta Pvt Ltd., a holding company owned by Dr. Sudhir Srivastava.
• As of September 30, 2023, Sushruta made advances aggregating to $16,980,000 under the line of credit note and exercised its option to convert the full amount of advances made into shares of our common stock at a conversion price of $0.74 per share.

Stakeholder Impact

• Shareholders are impacted by the restatement of financials and the identified material weaknesses in internal controls.
• Employees may be impacted by the company's efforts to remediate the material weaknesses and implement a new ERP system.
• Customers may be impacted by the company's ability to obtain regulatory approvals and scale up its operations.
• Creditors may be impacted by the company's ability to raise additional capital and continue as a going concern.

Next Steps

• The company is taking remedial actions to address the material weaknesses in internal controls.
• The company plans to implement a new ERP system to integrate business functions within the accounting and financial department.
• The company intends to continue its efforts to raise further funding to scale up operations and meet its longer-term capital needs.

Key Dates